Back to Cell Types

CCK-81Homo sapiens (Human)Cancer cell line

Also known as: CCK81

🤖 AI SummaryBased on 12 publications

Quick Overview

CCK-81 is a human colorectal cancer cell line used in cancer research.

Detailed Summary

CCK-81 is a human colorectal cancer cell line derived from a primary tumor. It is widely used in research to study the molecular mechanisms of colorectal cancer, including resistance to targeted therapies such as EGFR inhibitors. The cell line has been characterized for mutations in key oncogenes and tumor suppressor genes, including KRAS, BRAF, and TP53. CCK-81 is also used to investigate the role of Src family kinases in cancer progression and to evaluate the efficacy of kinase inhibitors. The cell line has been included in large-scale studies to understand the genetic and molecular heterogeneity of colorectal cancer and to identify potential therapeutic targets.

Research Applications

Study of molecular mechanisms of colorectal cancerInvestigation of resistance to targeted therapiesAnalysis of oncogene and tumor suppressor gene mutationsEvaluation of kinase inhibitorsUnderstanding genetic and molecular heterogeneity of colorectal cancer

Key Characteristics

Mutations in KRAS, BRAF, and TP53Used in studies of EGFR inhibitor resistanceCharacterized for Src family kinase activityIncluded in large-scale genomic and proteomic studies

Generated on 6/19/2025

Basic Information

Database ID	CVCL_2873
Species	Homo sapiens (Human)
Tissue Source	Lymph node[UBERON:UBERON_0000029]

Donor Information

Age	62
Age Category	Adult
Sex	Female
Subtype Features	MSI

Disease Information

Disease	Colon adenocarcinoma
Lineage	Bowel
Subtype	Colon Adenocarcinoma
OncoTree Code	COAD

DepMap Information

Source Type	HSRRB
Source ID	ACH-000963_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Pro278His (c.833C>A)	Heterozygous	-	from parent cell line CCK-81
MutationSimple	PIK3CA	p.Cys420Arg (c.1258T>C)	Heterozygous	-	from parent cell line JIMT-1
MutationSimple	FBXW7	p.Arg465Cys (c.1393C>T)	Heterozygous	-	from parent cell line CCRF-CEM

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,13

D13S317

9,12,13

D16S539

9,10

D21S11

28,31

D5S818

11,12,13

D7S820

8,8.1,10.3,12

TH01

6,8

TPOX

9,11

vWA

14,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Pharmacoproteomic characterisation of human colon and rectal cancer.

Weichert W., Knapp S., Feller S.M., Kuster B.

Mol. Syst. Biol. 13:951-951(2017).

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.

Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.

Clin. Cancer Res. 21:2157-2166(2015).

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mariadason J.M., Sieber O.M.

Cancer Res. 74:3238-3247(2014).

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

Orphanides G., French T., Wessels L.F.A.

BMC Med. Genomics 5:66.1-66.15(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Liu Y., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

Establishment of a human colon adenocarcinoma cell line producing carcinoembryonic antigen.

Koura M., Isaka H.

Gann 71:313-318(1980).